Abstract
In HCV genome, the NS5B RNA-dependent RNA polymerase (RdRp) plays central role in the replication. It is the most preferred target for design and screening of small molecule HCV inhibitors. From in house compound library screening using NS5B polymerase enzymatic assay, we identified some benzimidazole derivatives. The activities were predicted using the QSAR generated models. Along with QSAR predictions, molecular docking studies help to study binding of these series of compounds at allosteric pocket (AP-1).
Keywords: Benzimidazole derivatives, anti-HCV agents, NS5B polymerase inhibitors, molecular docking.
Graphical Abstract
Anti-Infective Agents
Title:QSAR and Molecular Docking Directed Synthesis and Preliminary Evaluation of Novel Non-Nucleoside HCV NS5B Polymerase Inhibitors
Volume: 15 Issue: 1
Author(s): Vaishali M. Patil*, Neeraj Masand, Gurukumar K. R, Maksim Chudayeu, Satya Prakash Gupta, Subeer Samanta and Neerja Kaushik-Basu
Affiliation:
- Department of Medicinal Chemistry, Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Subhartipuram, Meerut-250 004 Uttar Pradesh,India
Keywords: Benzimidazole derivatives, anti-HCV agents, NS5B polymerase inhibitors, molecular docking.
Abstract: In HCV genome, the NS5B RNA-dependent RNA polymerase (RdRp) plays central role in the replication. It is the most preferred target for design and screening of small molecule HCV inhibitors. From in house compound library screening using NS5B polymerase enzymatic assay, we identified some benzimidazole derivatives. The activities were predicted using the QSAR generated models. Along with QSAR predictions, molecular docking studies help to study binding of these series of compounds at allosteric pocket (AP-1).
Export Options
About this article
Cite this article as:
Patil M. Vaishali*, Masand Neeraj, R K. Gurukumar, Chudayeu Maksim, Gupta Prakash Satya, Samanta Subeer and Kaushik-Basu Neerja, QSAR and Molecular Docking Directed Synthesis and Preliminary Evaluation of Novel Non-Nucleoside HCV NS5B Polymerase Inhibitors, Anti-Infective Agents 2017; 15 (1) . https://dx.doi.org/10.2174/2211352514666161125124846
DOI https://dx.doi.org/10.2174/2211352514666161125124846 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design Molecular Targets of Mesalazine in Colorectal Cancer
Current Cancer Therapy Reviews Melatonin Causes Gene Expression in Aged Animals to Respond to Inflammatory Stimuli in a Manner Differing from that of Young Animals
Current Aging Science Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Applications of Human Umbilical Cord Blood Cells in Central Nervous System Regeneration
Current Stem Cell Research & Therapy Cytoprotection by Inhaled Carbon Monoxide before Cardiopulmonary Bypass in Preclinical Models
Current Pharmaceutical Biotechnology Production of Orally Applicable New Drug or Drug Combinations from Natural Origin Capsaicinoids for Human Medical Therapy
Current Pharmaceutical Design Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Changing the Endocrine Dependence of Breast Cancer: Data and Hypotheses
Current Medicinal Chemistry Treatment of Acute Hepatitis C
Current Pharmaceutical Design Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Frequency of Pathological Types of Hyperthyroidism in Thyroid Scan Patients
Current Medical Imaging